People with obesity consume more food than is needed to maintain an ideal body weight, despite the discrimination that accompanies being overweight and the wealth of available information that overconsumption is detrimental to health
Here are a few ways future formulations could shift the market: Oral (Rybelsus 2.0, better semaglutide formulations) What changes: Easier to prescribe and adhere to, but worse tolerability Where it moves: Into primary care lower friction, tighter payer control Strategic shift: More access, same adherence problem Risk: Higher churn, more side-effect driven dropout Next-gen combos (e.g., GLP-1 + GIP + amylin, muscle-sparing) What changes: Better outcomes, better tolerability Where it moves : Into specialist-aligned care models deeper payer integration Strategic shift: Drugs become platforms unlock long-term value Risk: Slow coverage without strong RWE
Can I take resveratrol and NMN together
Depression ALCAR shows promise in treating depression, with research dating back to the 1990s highlighting antidepressant-like effects through modulation of neurotransmitter systems [5]
Packaging and labels may vary slightly
